Summary of Key Points Core Viewpoint - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has successfully completed its initial public offering (IPO) of 25.7 million shares, with the shares set to be listed on the Shenzhen Stock Exchange on December 11, 2024. The total share capital post-IPO will be 102.8 million shares, with a significant portion subject to trading restrictions [1]. Group 1: IPO and Share Structure - The company received approval from the China Securities Regulatory Commission for its IPO, issuing 25.7 million shares, increasing the total share capital from 77.1 million to 102.8 million shares [1]. - After the IPO, 76.29% of the total shares will be subject to trading restrictions, while 23.71% will be freely tradable [1]. - Following a profit distribution plan approved at the 2024 annual shareholders' meeting, the total share capital will further increase to 133.64 million shares, with 76.29% still under trading restrictions [1]. Group 2: Lock-up Period and Compliance - Under the IPO terms, 10% of the shares allocated to offline investors will be subject to a 6-month lock-up period, while 90% will be tradable immediately upon listing [2]. - All shareholders holding restricted shares have complied with the lock-up commitments, and there are no violations affecting the listing of these shares [2]. Group 3: Changes in Share Capital Structure - The number of restricted shares decreased by 1,724,702 shares, resulting in 100,230,000 restricted shares, which is 75% of the total share capital post-IPO [4]. - The number of unrestricted shares increased to 33,410,000, representing 25% of the total share capital after the release of the lock-up [4]. Group 4: Sponsor's Verification - The sponsor has confirmed that the release of restricted shares complies with relevant regulations and that the company's disclosures regarding the restricted shares are accurate and complete [6].
博苑股份: 关于首次公开发行网下配售限售股份上市流通提示性公告